Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Scientists at Center of Molecular Immunology discuss research in cancer vaccines
November 18th, 2008
New investigation results, 'Immunization with a GM3 ganglioside nanoparticulated vaccine confers an effector CD8(+) T cells-mediated protection against melanoma B16 challenge,' are detailed in a study published in Cancer Immunology, Immunotherapy. According to a study from Havana, Cuba, "Preventive immunotherapy is an attractive strategy for patients at a high risk of having cancer. The success of prophylactic cancer vaccines would depend on the selection of target antigens that are essential for tumor growth and progression." "The overexpression of GM3 ganglioside in murine and human melanomas and its important role in tumor progression makes this self antigen a...
Source: Cancer Weekly (2008-11-18)
|
